Uroweb Guidelines

Our aim is to develop best practice clinical guidelines primarily for frontline urologists, but also for patients to support shared decision making and, increasingly, the shift to more individualised patient-centred care.

It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

Uroweb Guidelines

DOWNLOAD 🔥 https://fancli.com/2y3YQ0 🔥

A quick reference document (Pocket guidelines) is available. This is an abridged version which may require consultation together with the full text version. Several scientific publications are available [1,2] as are a number of translations of all versions of the PCa Guidelines. All documents can be accessed on the EAU website: -cancer/.

The European Association of Urology (EAU) Urological Infections Guidelines Panel has compiled these clinical guidelines to provide medical professionals with evidence-based information and recommendations for the prevention and treatment of urinary tract infections (UTIs) and male accessory gland infections. These guidelines also aim to address the important public health aspects of infection control and antimicrobial stewardship. Separate EAU guidelines documents are available addressing paediatric urological infections [1] and infections in patients with neurological urinary tract dysfunction [2].

It must be emphasised that clinical guidelines present the best evidence available to the experts. However, following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

It must be emphasised that guidelines present the best evidence available to the experts. However, following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - while taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

Nonetheless, scientific societies have tried to proceed with their aims to provide and share new research data and findings to improve patient care. In order to update the EAU Guidelines on Renal Cell Carcinoma (RCC), Guideline Panel members worked remotely during the past 7 months to be able to revise and deliver the recommendations for this new year. Novel and relevant evidences have been identified, collated and appraised through a structured assessment of the literature. A broad and comprehensive scoping search was performed, limited to studies representing a high certainty of evidence. Databases covered included Medline, EMBASE and the Cochrane Libraries. After deduplication, a total of 1,973 innovative papers were identified, obtained and screened for relevance. For each recommendation within the guidelines, a modified GRADE rating form was included as well. Specific chapters were updated by way of systematic reviews, commissioned and undertaken by the EAU RCC Guidelines Panel based on prioritised topics or questions.

The European Association of Urology (EAU) Renal Cell Cancer (RCC) Guidelines Panel has compiled these clinical guidelines to provide urologists with evidence-based information and recommendations for the management of RCC.

The RCC Guidelines Panel is an international group of clinicians consisting of urological surgeons, oncologists, methodologists, a pathologist and a radiologist, with particular expertise in the field of renal cancer care. Since 2015, the Panel has incorporated a patient advocate to provide a consumer perspective for its guidelines. All experts involved in the production of this document have submitted potential conflict of interest statements, which can be viewed on the EAU website Uroweb:

The European Association of Urology (EAU) Non-muscle-invasive Bladder Cancer (NMIBC) Guidelines Panel has compiled these clinical guidelines to provide clinicians with evidence-based information and recommendations for the management of upper urinary tract urothelial carcinoma (UTUC). Separate EAU guidelines are available addressing non-muscle-invasive bladder cancer [1], muscle-invasive and metastatic bladder cancer (MIBC) [2], and primary urethral carcinoma [3].

A quick reference document (Pocket guidelines) is available presenting the main findings of the UTUC Guidelines. This is an abridged version which may require consultation together with the full text version. Several scientific publications are available as are a number of translations of all versions of the EAU UTUC Guidelines. The most recent scientific summary was published in 2021 [4]. All documents are accessible through the EAU website: -urinary-tract-urothelial-cell-carcinoma/.

The European Association of Urology (EAU) Guidelines Panel for Muscle-invasive and Metastatic Bladder Cancer (MIBC) have prepared these guidelines to help urologists assess the evidence-based management of MIBC and to incorporate guideline recommendations into their clinical practice.

The EAU published its first guidelines on bladder cancer (BC) in 2000. This document covered both NMIBC and MIBC. Since these conditions require different treatment strategies, it was decided to give each condition its own guidelines, resulting in the first publication of separate MIBC Guidelines in 2004. This 2023 document presents a limited update of the 2022 version.

This overview represents the updated European Association of Urology (EAU) Guidelines for Non-muscle-invasive Bladder Cancer (NMIBC), TaT1 and carcinoma in situ (CIS). The information presented is limited to urothelial carcinoma (UC), unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations. Separate EAU Guidelines are available addressing upper tract urothelial carcinoma (UTUC) [1], muscle-invasive and metastatic bladder cancer (MIBC) [2] and primary urethral carcinoma [3]. It must be emphasised that clinical guidelines present the best evidence available to the experts, but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and references/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

A quick reference document (Pocket guidelines) is available. This is an abridged version which may require consultation together with the full text version. Several scientific publications are available, the latest publication dating to 2022 [4], as are a number of translations of all versions of the EAU NMIBC Guidelines. All documents are accessible through the EAU website Uroweb: -muscle-invasive-bladder-cancer/.

A quick reference document (Pocket guidelines) is available this is an abridged versions which may require consultation together with the full text version. A number of translated versions, alongside several scientific publications are also available [1-7]. All documents can be viewed through the EAU website:

-urology/.

The European Association of Urology (EAU) Urolithiasis Guidelines Panel has prepared these guidelines to help urologists assess evidence-based management of stones/calculi in the urinary tract and incorporate recommendations into clinical practice. This document covers most aspects of the disease, which is still a cause of significant morbidity despite technological and scientific advances. The Panel is aware of the geographical variations in healthcare provision. In addition, information on the management of bladder stones is now also included in these guidelines.

A quick reference document (Pocket guidelines) is available. This is an abridged versions, which may require consultation together with the full text versions. Several scientific publications are also available [1-3]. All documents can be accessed through the EAU website:

The aim of these guidelines is to present the current evidence for the diagnosis and treatment of patients with cancer of the testis. Testicular cancer (TC) represents 5% of urological tumours affecting mostly younger males. This document addresses post-pubertal testicular germ-cell tumours (TGCTs) in the male including spermatocytic tumour and sex cord/gonadal stromal tumours.

It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions which should also take personal values and references/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

A quick reference document (Pocket guidelines) is available, in print and on the EAU website. These are abridged versions which may require consultation together with the full text version. Several scientific publications are available, as are a number of translations of all versions of the EAU TC Guidelines. All documents are accessible through the EAU website:

A quick reference document (Pocket guidelines) is available. This is an abridged version which may require consultation together with the full text version. This 2023 updated document presents a complete revision of the prior (2018) publication. All prior versions can be viewed at the EAU website: -cancer. 2351a5e196